INNT
TOTAL INVALIDATION PROCESSED BY THE IB
09/01/2022
Voltar para busca
Dado oficial do USPTO
MEDIGENE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
44
Atualização mais recente
09/01/2022
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
27/04/2007
Data de registro
17/03/2009
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
26/02/2021
Última transação
26/02/2021
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
DE
Examinador
FRENCH, CURTIS
Unidade examinadora
M60
Localização atual
GENERIC WEB UPDATE
Titulares e representantes
Titulares
MediGene AG
Representantes
Adrienne L. White WRB-IP LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medicines for humans and animalsexcept venous-therapeuticsmedicines for treating cardiovascular and vascular diseasesdermatological disorders and diseasesprecancerous diseasesbenign and malignant tumorsinfectious diseasesallergic and asthmatic diseasesneurodegenerative diseasesautoimmune diseasesdiseases of the respiratory tractgastrointestinal diseasesblood disordersaging-associated diseasesgenetic disordersmetabolic disordersmusculoskeletal disorders and eye diseasesvaccines for treating cardiovascular and vascular diseasesdermatological disorders and diseasesprecancerous diseasesbenign and malignant tumorsinfectious diseasesallergic and asthmatic diseasesneurodegenerative diseasesautoimmune diseasesdiseases of the respiratory tractgastrointestinal diseasesblood disordersaging-associated diseasesgenetic disordersmetabolic disordersmusculoskeletal disorders and eye diseases; serumsimmune serums for passive vaccination for treating infectious diseasesdiagnostic test kits comprising antibodiesantibody fragmentsserumssoluble monoclonal T-cell receptorspeptidespeptide-analoguesenzymesliposomesdyesradioactively labeled substancesfor the purpose of testingdiagnosing and monitoring cardiovascular and vascular diseasesdermatological disorders and diseasesprecancerous diseasesbenign and malignant tumorsinfectious diseasesallergic and asthmatic diseasesneurodegenerative diseasesautoimmune diseasesdiseases of the respiratory tractgastrointestinal diseasesblood disordersaging-associated diseasesgenetic disordersmetabolic disordersmusculoskeletal disorders and eye diseases; proteinsproteinconjugatespeptidesenzymes and enzyme-preparationsantibodiesT-cell-proteinsattenuated virusesvirus-like particlesliposomesherbal extractscomponents of low molecular weightall for use as medicinesvaccines and parts of medical diagnostic test kits for treatingtestingdiagnosing and monitoring all diseases mentioned above
Publicações
Histórico de despachos e eventos da marca no USPTO.
44 publicações encontradas
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
01/12/2021
INPC
INVALIDATION PROCESSED
01/12/2021
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
26/10/2021
C71T
CANCELLED SECTION 71
26/02/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
23/08/2018
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
17/03/2018
RNWL
INTERNATIONAL REGISTRATION RENEWED
11/05/2017
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
23/03/2015
C75A
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
23/03/2015
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
23/03/2015
ES75
TEAS SECTION 71 & 15 RECEIVED
17/03/2015
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/01/2013
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
24/11/2009
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/07/2009
FIMP
FINAL DISPOSITION PROCESSED
01/07/2009
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
17/06/2009
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
27/03/2009
R.PR
REGISTERED-PRINCIPAL REGISTER
17/03/2009
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/03/2009
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
12/03/2009
PUBO
PUBLISHED FOR OPPOSITION
30/12/2008
NPUB
NOTICE OF PUBLICATION
10/12/2008
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
25/11/2008
ALIE
ASSIGNED TO LIE
25/11/2008
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
20/11/2008
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/11/2008
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
17/11/2008
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
17/11/2008
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
17/11/2008
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
17/11/2008
CNRT
NON-FINAL ACTION MAILED
21/05/2008
CNRT
NON-FINAL ACTION WRITTEN
21/05/2008
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
28/04/2008
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/04/2008
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
28/04/2008
RFNT
REFUSAL PROCESSED BY IB
16/11/2007
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
26/10/2007
RFRR
REFUSAL PROCESSED BY MPU
25/10/2007
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
25/10/2007
CNRT
NON-FINAL ACTION WRITTEN
24/10/2007
DOCK
ASSIGNED TO EXAMINER
12/10/2007
NWAP
NEW APPLICATION ENTERED
12/10/2007
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/10/2007
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MEDIGENE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.